Your browser doesn't support javascript.
loading
Visceral transplantation in patients with intestinal-failure associated liver disease: Evolving indications, graft selection, and outcomes.
Hawksworth, Jason S; Desai, Chirag S; Khan, Khalid M; Kaufman, Stuart S; Yazigi, Nada; Girlanda, Raffaele; Kroemer, Alexander; Fishbein, Thomas M; Matsumoto, Cal S.
Afiliación
  • Hawksworth JS; MedStar Georgetown University Hospital, MedStar Georgetown Transplant Institute, Washington, DC, USA.
  • Desai CS; Department of Surgery, Organ Transplant Service, Walter Reed National Military Medical Center, Bethesda, MD, USA.
  • Khan KM; Department of Surgery, Division of Abdominal Transplant, University of North Carolina, Chapel Hill, NC, USA.
  • Kaufman SS; MedStar Georgetown University Hospital, MedStar Georgetown Transplant Institute, Washington, DC, USA.
  • Yazigi N; MedStar Georgetown University Hospital, MedStar Georgetown Transplant Institute, Washington, DC, USA.
  • Girlanda R; MedStar Georgetown University Hospital, MedStar Georgetown Transplant Institute, Washington, DC, USA.
  • Kroemer A; MedStar Georgetown University Hospital, MedStar Georgetown Transplant Institute, Washington, DC, USA.
  • Fishbein TM; MedStar Georgetown University Hospital, MedStar Georgetown Transplant Institute, Washington, DC, USA.
  • Matsumoto CS; MedStar Georgetown University Hospital, MedStar Georgetown Transplant Institute, Washington, DC, USA.
Am J Transplant ; 18(6): 1312-1320, 2018 06.
Article en En | MEDLINE | ID: mdl-29498797
ABSTRACT
Intestinal failure (IF)-associated liver disease (IFALD) is widely recognized as a lethal complication of long-term parenteral nutrition. The pathophysiology of IFALD is poorly understood but appears to be multifactorial and related to the inflammatory state in the patient with IF. Visceral transplant for IFALD includes variants of intestine, liver, or combined liver-intestine allografts. Graft selection for an individual patient depends on the etiology of IF, abdominal and vascular anatomy, severity of IFALD, and potential for intestinal rehabilitation. The past decade has witnessed dramatic improvement in the management of IFALD, principally due to improved lipid emulsion formulations and the multidisciplinary care of the patient with IF. As the recognition and treatment of IFALD continue to improve, the requirement of liver-inclusive visceral grafts appears to be decreasing, representing a paradigm shift in the care of the patient with IF. This review highlights the current indications, graft selection, and outcomes of visceral transplantation for IFALD.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Vísceras / Enfermedades Intestinales / Hepatopatías Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Am J Transplant Asunto de la revista: TRANSPLANTE Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Vísceras / Enfermedades Intestinales / Hepatopatías Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Am J Transplant Asunto de la revista: TRANSPLANTE Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos